Portland Global Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Portland Global Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-67,523	Closed	-$2.15M	–	141
2025 Q1	$2.15M	Buy	67,523 +276	+0.4%	+$10.5K	0.27%	53
2024 Q4	$2.61M	Buy	67,247 +2,343	+4%	+$98.4K	0.33%	50
2024 Q3	$2.92M	Buy	64,904 +1,625	+3%	+$72.6K	0.37%	51
2024 Q2	$2.64M	Buy	63,279 +2,756	+5%	+$115K	0.36%	51
2024 Q1	$2.75M	Buy	60,523 +363	+0.6%	+$16.5K	0.38%	47
2023 Q4	$2.78M	Buy	60,160 +1,948	+3%	+$79.4K	0.42%	48
2023 Q3	$2.37M	Buy	58,212 +181	+0.3%	+$8.24K	0.4%	51
2023 Q2	$2.81M	Buy	58,031 +1,200	+2%	+$60K	0.46%	49
2023 Q1	$2.8M	Buy	56,831 +2,798	+5%	+$144K	0.48%	52
2022 Q4	$2.73M	Buy	54,033 +1,273	+2%	+$65.6K	0.5%	51
2022 Q3	$2.65M	Buy	52,760 +2,981	+6%	+$168K	0.53%	49
2022 Q2	$2.43M	Buy	+49,779	New	+$2.52M	0.47%	53

Other funds holding GNOM

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Insight Advisors Newtown, Pennsylvania $567M AUM 25.52% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

OCM

One Capital Management Westlake Village, California $3.6B AUM 16.02% 1-Year Est. Return

Portland Global Advisors's GNOM Position: Q2 2025 in Review

Portland Global Advisors sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q2 2025, closing a stake of 67,523 shares — an estimated $2.15M sold.

Portland Global Advisors first reported a position in GNOM in Q2 2022 and held it in 12 quarters. The position peaked at $2.92M in Q3 2024. 53 funds tracked by Wall St. Rank hold GNOM as of Q2 2025.

Portland Global Advisors reported no remaining Global X Genomics & Biotechnology ETF position as of Q2 2025 after selling out during the quarter.
Portland Global Advisors sold 67,523 Global X Genomics & Biotechnology ETF shares in Q2 2025, an estimated $2.15M.
Portland Global Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q2 2022 and held it in 12 quarters.
Portland Global Advisors's Global X Genomics & Biotechnology ETF position peaked at $2.92M in Q3 2024.
53 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2025.

Based on Portland Global Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.